Anticancer Drugs

O’Boyle, Niamh M; Meegan, Mary J

doi:10.3390/books978-3-03921-587-4

dc.contributor.author	O’Boyle, Niamh M	*
dc.contributor.author	Meegan, Mary J	*
dc.date.accessioned	2021-02-11T08:14:55Z
dc.date.available	2021-02-11T08:14:55Z
dc.date.issued	2019	*
dc.date.submitted	2019-12-09 11:49:15	*
dc.identifier	42571	*
dc.identifier.uri	https://directory.doabooks.org/handle/20.500.12854/40955
dc.description.abstract	The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody–drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients.	*
dc.language	English	*
dc.subject	QD1-999	*
dc.subject	Q1-390	*
dc.subject.classification	thema EDItEUR::P Mathematics and Science::PN Chemistry	en_US
dc.subject.other	graphene oxide	*
dc.subject.other	indole	*
dc.subject.other	androgens	*
dc.subject.other	cyclooxygenase-2	*
dc.subject.other	cyclooxygenase-1	*
dc.subject.other	heteropolysaccharide	*
dc.subject.other	drug conjugation	*
dc.subject.other	drug delivery	*
dc.subject.other	ellipticine	*
dc.subject.other	chemical linker	*
dc.subject.other	oesophageal cancer	*
dc.subject.other	antiproliferative activity	*
dc.subject.other	topoisomerase II	*
dc.subject.other	?-lactam	*
dc.subject.other	DSD	*
dc.subject.other	antibody	*
dc.subject.other	topoisomerase inhibitors	*
dc.subject.other	magnetic targeting	*
dc.subject.other	cisplatin resistance	*
dc.subject.other	steroidogenesis	*
dc.subject.other	[18F]FDG PET/CT	*
dc.subject.other	heterocyclic chemistry	*
dc.subject.other	dehydroepiandrosterone	*
dc.subject.other	antimitotic	*
dc.subject.other	3-vinylazetidin-2-ones	*
dc.subject.other	glioblastoma	*
dc.subject.other	and cancer therapy	*
dc.subject.other	intestinal mucositis	*
dc.subject.other	Combretastatin A-4	*
dc.subject.other	metabolism	*
dc.subject.other	anti-cancer drugs	*
dc.subject.other	maghemite	*
dc.subject.other	COX-1 inhibitor	*
dc.subject.other	anticancer	*
dc.subject.other	CYP17A1	*
dc.subject.other	conjugate and hybrid drugs	*
dc.subject.other	inflammation	*
dc.subject.other	snticancer drugs	*
dc.subject.other	P450c17	*
dc.subject.other	tumorigenesis	*
dc.subject.other	cisplatin	*
dc.subject.other	biomarker profiling	*
dc.subject.other	cancer drug design	*
dc.subject.other	tubulin	*
dc.subject.other	cytochrome P450	*
dc.subject.other	5-fluorouracil	*
dc.subject.other	prostate cancer	*
dc.subject.other	abiraterone	*
dc.subject.other	NCI screen	*
dc.subject.other	radiation	*
dc.subject.other	cancer immunotherapy	*
dc.subject.other	microtubule targeted drugs	*
dc.subject.other	cancer	*
dc.subject.other	treatment resistance	*
dc.title	Anticancer Drugs	*
dc.type	book
oapen.identifier.doi	10.3390/books978-3-03921-587-4	*
oapen.relation.isPublishedBy	46cabcaa-dd94-4bfe-87b4-55023c1b36d0	*
oapen.relation.isbn	9783039215867	*
oapen.relation.isbn	9783039215874	*
oapen.pages	214	*
oapen.edition	1st	*

Fichier(s) constituant ce document

Fichiers	Taille	Format	Vue
Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Imported or submitted locally

Afficher la notice abrégée

Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by-nc-nd/4.0/